Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Basilea Pharmaceutica AG Allschwil stock

BSLN.SW
CH0011432447
A0B9GA

Price

42.20
Today +/-
-0.32
Today %
-0.71 %
P

Basilea Pharmaceutica AG Allschwil stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Basilea Pharmaceutica AG Allschwil stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Basilea Pharmaceutica AG Allschwil stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Basilea Pharmaceutica AG Allschwil stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Basilea Pharmaceutica AG Allschwil's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Basilea Pharmaceutica AG Allschwil Stock Price History

DateBasilea Pharmaceutica AG Allschwil Price
11/8/202442.20 undefined
11/7/202442.50 undefined
11/6/202442.60 undefined
11/5/202443.10 undefined
11/4/202443.65 undefined
11/1/202443.20 undefined
10/31/202442.80 undefined
10/30/202443.50 undefined
10/29/202443.65 undefined
10/28/202444.55 undefined
10/25/202444.85 undefined
10/24/202444.20 undefined
10/23/202444.65 undefined
10/22/202444.40 undefined
10/21/202445.00 undefined
10/18/202445.60 undefined
10/17/202444.80 undefined
10/16/202444.95 undefined
10/15/202445.25 undefined
10/14/202445.65 undefined

Basilea Pharmaceutica AG Allschwil Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Basilea Pharmaceutica AG Allschwil, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Basilea Pharmaceutica AG Allschwil from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Basilea Pharmaceutica AG Allschwil’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Basilea Pharmaceutica AG Allschwil. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Basilea Pharmaceutica AG Allschwil’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Basilea Pharmaceutica AG Allschwil’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Basilea Pharmaceutica AG Allschwil’s growth potential.

Basilea Pharmaceutica AG Allschwil Revenue, EBIT and net profit per share

DateBasilea Pharmaceutica AG Allschwil RevenueBasilea Pharmaceutica AG Allschwil EBITBasilea Pharmaceutica AG Allschwil Net Income
2028e217.95 M undefined85 M undefined75.84 M undefined
2027e239.91 M undefined91.16 M undefined77.42 M undefined
2026e254.81 M undefined75.7 M undefined63.22 M undefined
2025e222.44 M undefined48.01 M undefined42.89 M undefined
2024e204.07 M undefined39.13 M undefined47.75 M undefined
2023157.63 M undefined19.21 M undefined10.45 M undefined
2022147.77 M undefined18.54 M undefined12.15 M undefined
2021148.12 M undefined1.17 M undefined-6.83 M undefined
2020127.63 M undefined-23.26 M undefined-14.72 M undefined
2019134.38 M undefined-17.2 M undefined-22.42 M undefined
2018132.56 M undefined-24.1 M undefined-31.35 M undefined
2017101.52 M undefined-17.05 M undefined-19.36 M undefined
201665.98 M undefined-43.89 M undefined-51.29 M undefined
201551.65 M undefined-61.49 M undefined-61.6 M undefined
201442.5 M undefined-41.83 M undefined-41.55 M undefined
201341 M undefined-33.3 M undefined-33 M undefined
201257.9 M undefined-50.8 M undefined-53 M undefined
201166.7 M undefined-57.3 M undefined-57.6 M undefined
2010116.2 M undefined-16.5 M undefined107.6 M undefined
200926.5 M undefined-120.3 M undefined-120.7 M undefined
200811.8 M undefined-152.5 M undefined-143.5 M undefined
20077.9 M undefined-136.5 M undefined-126.8 M undefined
20067.4 M undefined-87.9 M undefined-85.1 M undefined
200530.5 M undefined-50.8 M undefined-49.6 M undefined
2004300,000 undefined-75.7 M undefined-75.5 M undefined

Basilea Pharmaceutica AG Allschwil Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
00030771126116665741425165101132134127148147157204222254239217
-----76.67-57.14136.36346.15-43.10-13.64-28.072.4421.4327.4555.3830.691.52-5.2216.54-0.686.8029.948.8214.41-5.91-9.21
-----100.00100.0092.3197.4196.9792.98100.00--92.3191.0984.8585.8281.1083.7883.6782.80-----
000007112411364534100609211211510312412313000000
-62-55-75-50-87-136-152-120-16-57-50-33-41-61-43-17-24-17-23118193948759184
----166.67-1,242.86-1,942.86-1,381.82-461.54-13.79-86.36-87.72-80.49-97.62-119.61-66.15-16.83-18.18-12.69-18.110.6812.2412.1019.1221.6229.5338.0838.71
-59-55-75-49-85-126-143-120107-57-53-33-41-61-51-19-31-22-14-612104742637775
--6.7836.36-34.6773.4748.2413.49-16.08-189.17-153.27-7.02-37.7424.2448.78-16.39-62.7563.16-29.03-36.36-57.14-300.00-16.67370.00-10.6450.0022.22-2.60
55.26.97.47.79.19.69.69.69.69.69.79.9510.1110.1210.8510.8410.7610.2811.6811.8611.9900000
---------------------------
Details

Keystats

Revenue and Growth

The Basilea Pharmaceutica AG Allschwil Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Basilea Pharmaceutica AG Allschwil is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                           
112.175.5203.2229.6176.6424.8293.6178.4283197.1344273.9226.13364.69239.03260.72223.03129.02161.77148.784.6659.93
0.900.10.40.20.32.32.47.810.57.63.91.171.552.494.963.766.248.71033.1527.89
5.61.10.60.6135.82.63.22.23.93.47.043.014.9210.0731.8424.0723.68028.5530.26
0000000.10.144.1004.99.5814.9315.3214.4118.5721.1922.7824.2426.41
1.30.521.74.55.82.92.41.65.64.755.336.047.121.911.76.958.175.144.767.65
119.977.1205.9232.3182.3433.9304.7185.9299.6219.5360.2286.2244.57384.87268.49292.98274.74184.86223.53176.62175.36152.14
26.726.321.719.818.219.320.217.715.616.214.41312.1610.728.887.776.425.165.282.9221.5720.55
0000000000000050500300000
00000000000000000002.391.270
000002.62.82.111.20.60.40.220.350.230.330.370.370.670.630.580.55
0000000000000000000000
3.83.63.33.42.65.70.50.90.40.30.20.10.432.80.150.10.221.070.320.2622.070.04
30.529.92523.220.827.623.520.71717.715.213.512.8113.8759.2658.197.0136.616.276.245.4821.14
150.4107230.9255.5203.1461.5328.2206.6316.6237.2375.4299.7257.38398.74327.76351.17281.75221.47229.79182.82220.85173.29
                                           
505.37.47.47.89.59.69.69.69.69.610.210.5810.811.8111.8711.8811.8811.9212.9913.0913.1
00000000000000000001.031.041.04
75.485202.2160.4104.5325.6190.288.1200.7143.7112.372.561.3721.92-20.94-33.11-55.05-74.32-33.95-1,023.22-1,011.07-1,000.89
0000000000-16.4-11.8-14.01-17.87-24.87-19.2-16.28-24.56-27.25-21.62-3.79-10.21
0000000000000000000000
125.490.3209.6167.8112.3335.1199.897.7210.3153.3105.570.957.9314.86-34-40.44-59.45-87-49.28-2.0535.3644
4.50.620.91.92.81.821.21.41.71.72.111.091.854.356.46.7713.1510.620.195.85
0000000016.319.512.213.812.815.214.919.626.729.329.0533.4527.8617.66
9.75.28.818.225.433.141.532.840.113.244.744.846.7852.5456.1655.5433.5939.437.966.839.338.63
0.30.510.40000000000000000000
0000000000000000000123.5137.4715.45
14.56.321.219.127.335.943.334.857.634.158.660.361.6968.8472.9179.4966.6875.4950.16174.4174.8547.59
10.610.400000000000194.71195.47196.22196.98197.74239.6794.54131.3695.46
0000000000000000000000
00068.763.490.485.174.148.849.8211.2168.6137.76120.3494.38116.8984.7741.1942.0136.9235.3540.25
10.610.4068.763.490.485.174.148.849.8211.2168.6137.76315.04289.84313.11281.75238.93281.68131.47166.71135.7
25.116.721.287.890.7126.3128.4108.9106.483.9269.8228.9199.45383.88362.76392.6348.44314.43331.84305.87241.56183.29
150.5107230.8255.6203461.4328.2206.6316.7237.2375.3299.8257.38398.74328.76352.16288.99227.43282.56303.83276.92227.3
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Basilea Pharmaceutica AG Allschwil provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Basilea Pharmaceutica AG Allschwil's financial health and stability.

Assets

Basilea Pharmaceutica AG Allschwil's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Basilea Pharmaceutica AG Allschwil must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Basilea Pharmaceutica AG Allschwil after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Basilea Pharmaceutica AG Allschwil's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-59-55-75-49-85-126-143-120107-57-53-33-41-61-51-19-31-22-14-61210
3443324542322221111011
0000000000000000000000
-10-2477034-6-13-15-33192-32-38-17-3431-56-46-30-31-10-3
1113911191410653598573-9546
0000000000000005554769
0000000000000000000000
-64-52-6434-72-79-127-114106-82148-59-71-67-7519-79-63-54-32714
-22-40-1-1-6-5-1-1-3-1-1-1-10000-20-3-1
5665-135-6458-12134148-86121-96-3683171-60590-34391-1
7969-134-6360-11540150-85125-95-3585181-59600-324940
0000000000000000000000
900-10000000000194000043-23-49-59
0201923213331000038241302-5143942
920192-72133310000-92420802-514516-45-57
-------------------3.00---
00000000000-480000000000
133-7-376133-9134193951-10537156-74-38-26-62-44-1153-44
-86.8-56.8-64.633.2-74.1-85.5-132.4-116.3105.4-85.9146.9-60.7-72.77-69.09-75.4318.07-79.82-64.24-56.4-32.883.7513.21
0000000000000000000000

Basilea Pharmaceutica AG Allschwil stock margins

The Basilea Pharmaceutica AG Allschwil margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Basilea Pharmaceutica AG Allschwil. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Basilea Pharmaceutica AG Allschwil.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Basilea Pharmaceutica AG Allschwil's sales revenue. A higher gross margin percentage indicates that the Basilea Pharmaceutica AG Allschwil retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Basilea Pharmaceutica AG Allschwil's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Basilea Pharmaceutica AG Allschwil's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Basilea Pharmaceutica AG Allschwil's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Basilea Pharmaceutica AG Allschwil. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Basilea Pharmaceutica AG Allschwil's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Basilea Pharmaceutica AG Allschwil Margin History

Basilea Pharmaceutica AG Allschwil Gross marginBasilea Pharmaceutica AG Allschwil Profit marginBasilea Pharmaceutica AG Allschwil EBIT marginBasilea Pharmaceutica AG Allschwil Profit margin
2028e83 %39 %34.8 %
2027e83 %38 %32.27 %
2026e83 %29.71 %24.81 %
2025e83 %21.58 %19.28 %
2024e83 %19.17 %23.4 %
202383 %12.18 %6.63 %
202283.35 %12.55 %8.22 %
202183.75 %0.79 %-4.61 %
202081.15 %-18.22 %-11.53 %
201985.96 %-12.8 %-16.69 %
201884.69 %-18.18 %-23.65 %
201791.11 %-16.79 %-19.07 %
201691.9 %-66.51 %-77.73 %
201583 %-119.03 %-119.26 %
201483 %-98.43 %-97.76 %
2013100 %-81.22 %-80.49 %
201292.4 %-87.74 %-91.54 %
201196.4 %-85.91 %-86.36 %
201098.02 %-14.2 %92.6 %
200993.96 %-453.96 %-455.47 %
200897.46 %-1,292.37 %-1,216.1 %
2007100 %-1,727.85 %-1,605.06 %
200683 %-1,187.84 %-1,150 %
200583 %-166.56 %-162.62 %
200483 %-25,233.33 %-25,166.67 %

Basilea Pharmaceutica AG Allschwil Stock Sales Revenue, EBIT, Earnings per Share

The Basilea Pharmaceutica AG Allschwil earnings per share therefore indicates how much revenue Basilea Pharmaceutica AG Allschwil has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Basilea Pharmaceutica AG Allschwil earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Basilea Pharmaceutica AG Allschwil's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Basilea Pharmaceutica AG Allschwil’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Basilea Pharmaceutica AG Allschwil's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Basilea Pharmaceutica AG Allschwil Revenue, EBIT and net profit per share

DateBasilea Pharmaceutica AG Allschwil Sales per ShareBasilea Pharmaceutica AG Allschwil EBIT per shareBasilea Pharmaceutica AG Allschwil Earnings per Share
2028e17.98 undefined0 undefined6.26 undefined
2027e19.79 undefined0 undefined6.39 undefined
2026e21.02 undefined0 undefined5.22 undefined
2025e18.35 undefined0 undefined3.54 undefined
2024e16.84 undefined0 undefined3.94 undefined
202313.15 undefined1.6 undefined0.87 undefined
202212.46 undefined1.56 undefined1.02 undefined
202112.68 undefined0.1 undefined-0.58 undefined
202012.41 undefined-2.26 undefined-1.43 undefined
201912.49 undefined-1.6 undefined-2.08 undefined
201812.23 undefined-2.22 undefined-2.89 undefined
20179.36 undefined-1.57 undefined-1.79 undefined
20166.52 undefined-4.34 undefined-5.07 undefined
20155.11 undefined-6.08 undefined-6.09 undefined
20144.27 undefined-4.2 undefined-4.17 undefined
20134.23 undefined-3.43 undefined-3.4 undefined
20126.03 undefined-5.29 undefined-5.52 undefined
20116.95 undefined-5.97 undefined-6 undefined
201012.1 undefined-1.72 undefined11.21 undefined
20092.76 undefined-12.53 undefined-12.57 undefined
20081.23 undefined-15.89 undefined-14.95 undefined
20070.87 undefined-15 undefined-13.93 undefined
20060.96 undefined-11.42 undefined-11.05 undefined
20054.12 undefined-6.86 undefined-6.7 undefined
20040.04 undefined-10.97 undefined-10.94 undefined

Basilea Pharmaceutica AG Allschwil business model

Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil is one of the most popular companies on Eulerpool.com.

Basilea Pharmaceutica AG Allschwil SWOT Analysis

Strengths

Basilea Pharmaceutica AG has several key strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong portfolio of innovative and effective drugs
  • Robust research and development capabilities
  • Solid financial position and revenue growth
  • Established partnerships with leading healthcare organizations
  • Strong brand reputation and recognition

Weaknesses

Despite its strengths, Basilea Pharmaceutica AG also faces certain weaknesses that need to be addressed:

  • Limited product diversification
  • Reliance on a few key drugs for revenue generation
  • Higher production costs compared to some competitors
  • Lesser market presence in certain geographical regions

Opportunities

Basilea Pharmaceutica AG can capitalize on the following opportunities to enhance its growth and market position:

  • Expanding into emerging markets with unmet medical needs
  • Developing strategic alliances with complementary pharmaceutical companies
  • Investing in research and development of new drug candidates
  • Addressing the growing demand for personalized medicine

Threats

Basilea Pharmaceutica AG should also be mindful of the following threats that could impact its business operations:

  • Increasing competition from new entrants and generic drug manufacturers
  • Stringent regulatory requirements and approval processes
  • Price pressure and reimbursement challenges in healthcare systems
  • Intellectual property infringements and patent expirations

Basilea Pharmaceutica AG Allschwil Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Basilea Pharmaceutica AG Allschwil historical P/E ratio, EBIT multiple, and P/S ratio

Basilea Pharmaceutica AG Allschwil shares outstanding

The number of shares was Basilea Pharmaceutica AG Allschwil in 2023 — This indicates how many shares 11.991 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Basilea Pharmaceutica AG Allschwil earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Basilea Pharmaceutica AG Allschwil's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Basilea Pharmaceutica AG Allschwil’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Basilea Pharmaceutica AG Allschwil's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Basilea Pharmaceutica AG Allschwil dividend history and estimates

In 2023, Basilea Pharmaceutica AG Allschwil paid a dividend amounting to 0 CHF. Dividend means that Basilea Pharmaceutica AG Allschwil distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Basilea Pharmaceutica AG Allschwil provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Basilea Pharmaceutica AG Allschwil’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Basilea Pharmaceutica AG Allschwil's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Basilea Pharmaceutica AG Allschwil Dividend History

DateBasilea Pharmaceutica AG Allschwil Dividend
20135 undefined

Basilea Pharmaceutica AG Allschwil dividend payout ratio

In 2023, Basilea Pharmaceutica AG Allschwil had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Basilea Pharmaceutica AG Allschwil distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Basilea Pharmaceutica AG Allschwil represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Basilea Pharmaceutica AG Allschwil could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Basilea Pharmaceutica AG Allschwil's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Basilea Pharmaceutica AG Allschwil Payout Ratio History

DateBasilea Pharmaceutica AG Allschwil Payout ratio
2028e0 %
2027e0 %
2026e0 %
2025e0 %
2024e0 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
20150 %
20140 %
2013-147.06 %
20120 %
20110 %
20100 %
20090 %
20080 %
20070 %
20060 %
20050 %
20040 %

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Basilea Pharmaceutica AG Allschwil.

Basilea Pharmaceutica AG Allschwil latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.96 1.61  (67.92 %)2024 Q2
12/31/2023-2.05 -1.56  (23.72 %)2023 Q4
6/30/20230.82 2.42  (194.73 %)2023 Q2
12/31/2022-0.84 2.05  (345.1 %)2022 Q4
6/30/2022-1.58 -1.03  (34.85 %)2022 Q2
12/31/20210.07 1.26  (1,664.71 %)2021 Q4
6/30/2021-1.03 -1.84  (-78.61 %)2021 Q2
12/31/2020-2.44 -2.35  (3.6 %)2020 Q4
6/30/2020-1.99 0.92  (146.14 %)2020 Q2
12/31/2019-1.25 -0.64  (48.85 %)2019 Q4
1
2
3

Eulerpool ESG Scorecard© for the Basilea Pharmaceutica AG Allschwil stock

Eulerpool World ESG Rating (EESG©)

68/ 100

🌱 Environment

76

👫 Social

52

🏛️ Governance

75

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Basilea Pharmaceutica AG Allschwil shareholders

%
Name
Stocks
Change
Date
6.88349 % UBS Asset Management (Switzerland)834,359440,9014/30/2024
5.33954 % Black Creek Investment Management, Inc.647,215-16,45510/28/2024
5.29706 % CI Global Asset Management642,0653,82512/31/2023
3.00860 % Z¿rcher Kantonalbank (Asset Management)364,67809/30/2024
2.93453 % The Vanguard Group, Inc.355,699-4,7069/30/2024
2.74396 % ACATIS Investment Kapitalverwaltungsgesellschaft GmbH332,60008/31/2024
1.42858 % JPMorgan Asset Management U.K. Limited173,161012/31/2023
1.40185 % BlackRock Institutional Trust Company, N.A.169,9206459/30/2024
0.96267 % Norges Bank Investment Management (NBIM)116,687-73,3086/30/2024
0.80378 % Dimensional Fund Advisors, L.P.97,42808/31/2024
1
2
3
4
5
...
10

Basilea Pharmaceutica AG Allschwil Executives and Management Board

Mr. David Veitch(59)
Basilea Pharmaceutica AG Allschwil Chief Executive Officer, Member of the Management Committee
Compensation 1.75 M
Mr. Domenico Scala(58)
Basilea Pharmaceutica AG Allschwil Non-Executive Independent Chairman of the Board (since 2011)
Compensation 337,675
Dr. Thomas Werner(68)
Basilea Pharmaceutica AG Allschwil Non-Executive Independent Vice Chairman of the Board (since 2011)
Compensation 224,798
Dr. Alf Nicklasson(69)
Basilea Pharmaceutica AG Allschwil Non-Executive Independent Director (since 2013)
Compensation 211,749
Dr. Nicole Onetto(71)
Basilea Pharmaceutica AG Allschwil Non-Executive Independent Director
Compensation 192,132
1
2
3

Basilea Pharmaceutica AG Allschwil Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,750,790,890,640,72-0,12
SupplierCustomer0,730,510,140,33-0,43-0,68
SupplierCustomer0,590,58-0,27-0,43-0,45-0,71
SupplierCustomer0,590,110,330,16-0,090,32
SupplierCustomer0,330,01-0,54
SupplierCustomer0,310,38-0,13-0,65-0,65-0,75
SupplierCustomer0,18-0,41-0,02-0,33-0,63-0,55
SupplierCustomer0,09-0,24-0,010,560,71-0,24
SupplierCustomer0,080,310,830,640,820,68
SupplierCustomer-0,190,370,060,61-0,40-0,68
1

Most common questions regarding Basilea Pharmaceutica AG Allschwil

What values and corporate philosophy does Basilea Pharmaceutica AG Allschwil represent?

Basilea Pharmaceutica AG represents values of innovation, collaboration, and patient-centric approach. As a leading biopharmaceutical company, Basilea focuses on discovering, developing, and marketing novel medications to address critical medical needs. With a commitment to scientific excellence, the company strives to improve patient outcomes and quality of life through its research and development efforts. Basilea embraces a corporate philosophy that emphasizes integrity, transparency, and ethical conduct in all aspects of its operations. By consistently delivering breakthrough therapies, Basilea Pharmaceutica AG aims to make a meaningful impact on global healthcare.

In which countries and regions is Basilea Pharmaceutica AG Allschwil primarily present?

Basilea Pharmaceutica AG is primarily present in several key countries and regions. The company is based in Switzerland and has a significant presence in Europe, including Germany, France, the United Kingdom, and Italy. It also operates in the United States, where it has a commercial presence and collaborates with local partners. Basilea Pharmaceutica AG strives to expand its global reach, with a focus on markets in Asia, particularly China and Japan. With its headquarters in Basel, Switzerland, the company maintains a strong presence in its home country and is continuously exploring opportunities for growth and market expansion worldwide.

What significant milestones has the company Basilea Pharmaceutica AG Allschwil achieved?

Basilea Pharmaceutica AG has achieved numerous significant milestones throughout its history. Some notable achievements include the approval of Cresemba (isavuconazole) in multiple countries for the treatment of invasive aspergillosis and mucormycosis, as well as the approval of Zevtera (ceftobiprole) for the treatment of respiratory tract infections. Additionally, Basilea has successfully advanced several late-stage development programs, such as derazantinib for the treatment of bile duct cancer and lisavanbulin for the treatment of glioblastoma. The company's commitment to research and innovation has positioned Basilea as a leader in the pharmaceutical industry, consistently achieving significant milestones to improve patient care.

What is the history and background of the company Basilea Pharmaceutica AG Allschwil?

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company that specializes in the research and development of innovative medicines in the therapeutic areas of oncology and infectious diseases. Established in 2000, Basilea has since focused on discovering and advancing novel drugs to address unmet medical needs. With a strong commitment to scientific excellence, Basilea has made significant breakthroughs and has successfully brought several innovative drugs to the market. The company's dedication to improving patient outcomes has garnered recognition and collaborations with renowned pharmaceutical companies worldwide. Basilea Pharmaceutica AG continues to strive for cutting-edge solutions and advancements in the field of pharmaceuticals.

Who are the main competitors of Basilea Pharmaceutica AG Allschwil in the market?

Basilea Pharmaceutica AG faces competition from other pharmaceutical companies in the market. Some of its main competitors include Roche Holding AG, Novartis AG, Pfizer Inc., and GlaxoSmithKline plc.

In which industries is Basilea Pharmaceutica AG Allschwil primarily active?

Basilea Pharmaceutica AG is primarily active in the pharmaceutical industry.

What is the business model of Basilea Pharmaceutica AG Allschwil?

The business model of Basilea Pharmaceutica AG is focused on research, development, and commercialization of innovative pharmaceutical products to address medical needs in the therapeutic areas of oncology, hematology, and infectious diseases. The company utilizes its expertise in drug discovery and development to create novel medicines that aim to improve patient outcomes. By leveraging strategic partnerships and collaborations, Basilea Pharmaceutica AG seeks to bring these innovative therapies to market, ultimately improving the lives of patients worldwide.

What is the P/E ratio of Basilea Pharmaceutica AG Allschwil 2024?

The Basilea Pharmaceutica AG Allschwil P/E ratio is 10.6.

What is the P/S ratio of Basilea Pharmaceutica AG Allschwil 2024?

The Basilea Pharmaceutica AG Allschwil P/S ratio is 2.48.

What is the Quality Investing of Basilea Pharmaceutica AG Allschwil?

The Quality Investing for Basilea Pharmaceutica AG Allschwil is 5/10.

What is the revenue of Basilea Pharmaceutica AG Allschwil 2024?

The expected Basilea Pharmaceutica AG Allschwil revenue is 204.07 M CHF.

How high is the profit of Basilea Pharmaceutica AG Allschwil 2024?

The expected Basilea Pharmaceutica AG Allschwil profit is 47.75 M CHF.

What is the business model of Basilea Pharmaceutica AG Allschwil

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company that focuses on the development and marketing of medications for the therapeutic field. The company is divided into three business segments: research and development, production, and marketing and sales. In the research and development area, Basilea works on new active substances for the treatment of serious diseases such as cancer, bacterial infections, and mycoses. The company utilizes modern technologies and methods such as the inhibition of signaling molecules involved in the growth of tumor cells, or the blocking of enzymes required for bacterial proliferation. The production focuses on manufacturing high-quality and high-volume drugs. Basilea adheres to the highest international standards and has state-of-the-art production facilities. In addition to its own production, the company also collaborates with external partners and licensees to achieve greater market penetration. The marketing and sales segment is responsible for product marketing and expanding into new markets. Basilea collaborates with partners both domestically and internationally to offer a wide range of products. The company employs targeted marketing to convince as many patients and doctors as possible of the benefits of their medications. Basilea's portfolio includes medications for diseases such as invasive aspergillosis, resistant staphylococcal infections, and acute myeloid leukemia. One of the company's most well-known and successful products is the active substance Ceftobiprol, which is used for the treatment of severe bacterial infections. The portfolio also includes the medications Zevtera and Cresemba, which are approved in various countries and have already been successfully marketed. In recent years, Basilea has expanded its business field through targeted investments and collaborations. For example, the company has obtained new market approvals in Europe and the USA and entered into additional distribution partnerships. Basilea has also advanced its collaboration with other companies, universities, and research institutions to drive the development of new active substances and strengthen the company's innovation power. Overall, Basilea relies on close cooperation with other companies and partners to secure market success through targeted investments and research collaborations. Through its consistent focus on the needs of patients and doctors, as well as the high innovation and quality of its products, Basilea Pharmaceutica AG is on track to become an important player in the biopharmaceutical industry.

What is the Basilea Pharmaceutica AG Allschwil dividend?

Basilea Pharmaceutica AG Allschwil pays a dividend of 0 CHF distributed over payouts per year.

How often does Basilea Pharmaceutica AG Allschwil pay dividends?

The dividend cannot currently be calculated for Basilea Pharmaceutica AG Allschwil or the company does not pay out a dividend.

What is the Basilea Pharmaceutica AG Allschwil ISIN?

The ISIN of Basilea Pharmaceutica AG Allschwil is CH0011432447.

What is the Basilea Pharmaceutica AG Allschwil WKN?

The WKN of Basilea Pharmaceutica AG Allschwil is A0B9GA.

What is the Basilea Pharmaceutica AG Allschwil ticker?

The ticker of Basilea Pharmaceutica AG Allschwil is BSLN.SW.

How much dividend does Basilea Pharmaceutica AG Allschwil pay?

Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 11.85 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.

What is the dividend yield of Basilea Pharmaceutica AG Allschwil?

The current dividend yield of Basilea Pharmaceutica AG Allschwil is 11.85 %.

When does Basilea Pharmaceutica AG Allschwil pay dividends?

Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Basilea Pharmaceutica AG Allschwil?

Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.

What is the dividend of Basilea Pharmaceutica AG Allschwil?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Basilea Pharmaceutica AG Allschwil located?

Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.

Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.

When did Basilea Pharmaceutica AG Allschwil pay the last dividend?

The last dividend was paid out on 6/21/2013.

What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?

In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.

In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?

The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.

All fundamentals about Basilea Pharmaceutica AG Allschwil

Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.